Bezuclastinib

Name: Bezuclastinib in Nonadvanced systemic mastocytosis: Mechanism of action
Published: 2026-09-14T15:39:06-04:00

Nonadvanced systemic mastocytosis

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the second half of 2026
Last updated: September 17, 2026

Section

Product information and disease description Product description Product information Pharmacology

Mechanism of action

1 evidence topic · 1 source

Drug class and mechanism of action

“an oral, potent, and selective type 1 tyrosine kinase inhibitor (TKI) with activity against KIT D816V.” (opens the source at this quote in a new tab)